Oxford Science Enterprises
Venture capitalOxford · Pre-Seed–Growth · 78 people tracked
Investment thesis
Oxford Science Enterprises transforms world-class research into companies capable of solving major global challenges while delivering returns for investors. Operating through a unique partnership with the University of Oxford, it works with leading scientists, entrepreneurs and global investors to co-create and build transformational ventures. The firm partners with researchers and innovators across Oxford, Harwell and Culham to explore commercial potential and provides patient capital to fund and scale companies from pre-seed through growth. It positions itself as a venture-building engine with a diverse pipeline aimed at creating billion-pound deep-science companies.
Source: firm website, verified Aug 3, 2026.
Team · 78 people
from the firm's website & public directories
What they invest in
from 11 of 84 portfolio companiesDeep Tech ×5Biotech ×4Hardware ×3Medical Devices ×3AI & Machine Learning ×2Cleantech ×2Enterprise Software ×2New Materials ×2
HQs:United Kingdom×8United States×1
Investments · 84 tracked
founders shown can be your intro pathOxford Quantum Circuits (OQC) develops and operates superconducting quantum computers for commercial and strategic applications, offering Quantum-Compute-as-a-Service and integrating quantum systems directly into commercial data centres.
Deep TechEnterprise SoftwareHardwareQuantum ComputingOxford, GB
Peter Leek(Founder & CSO)Gerald Mullally(CEO)Simon Phillips(CTO)Nikki Cooper(CLO)Robert Coutts(CFO)Jack Boyer(Chairman of the Board)
Redefining treatment of incurable blood cancers by targeting the cells that drive them.
Amber Therapeutics develops medical technology focused on treating mixed urinary incontinence, advancing toward pivotal clinical trials in the US with expanded feasibility studies in Europe.
Medical Devices
BiotechBoston, US
Justian Craig Fox(Director)Donmienne Leung(Director)Laurence Barker(Director)Timothy Edwards(Director)Joanna Wolak(Executive Officer, Director)Jonathan Behr(Director)
FluoRok, a spin-out of the University of Oxford, develops patented fluorinating technologies to produce fluorochemicals such as Li-ion battery electrolytes, agrochemicals, and pharmaceutical ingredients without generating toxic hydrofluoric acid.
CleantechDeep TechNew Materials
Gabriele Pupo(CEO & Founder)Véronique Gouverneur(Founder)
Greywolf is a clinical-stage biotech developing antigen modulation therapies, including oral small molecules in Phase 1/2 trials, for people with cancers and autoimmune disorders.
BiotechDigital HealthHealthtechMedical DevicesOxford, GB
Peter Joyce(Co-founder)Tom McCarthy(Co-founder)
A therapeutics company developing checkpoint agonist antibodies for autoimmune disease treatment based on Oxford University research (exited August 2022).
Biotech company founded by Dame Carol Robinson building on native mass spectrometry for small molecule drug discovery.
Developing quantum computing technology.
Frequently asked questions
- What stage does Oxford Science Enterprises invest at?
- Oxford Science Enterprises invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth stages.
- What is Oxford Science Enterprises's typical check size?
- Oxford Science Enterprises typically writes checks of $63.5K – $31.8M.
- What sectors does Oxford Science Enterprises focus on?
- Oxford Science Enterprises focuses on AgTech, AI & Machine Learning, Biotech, Cleantech, Climate Tech, Deep Tech, Energy, Healthtech, Medical Devices, Quantum Computing, Robotics, Sector Agnostic.
- Where is Oxford Science Enterprises located?
- Oxford Science Enterprises is headquartered in Oxford, GB.
- Does Oxford Science Enterprises lead rounds?
- Yes, Oxford Science Enterprises leads investment rounds.
Images
Co-investors · 4
GV (formerly Google Ventures) is a venture investment firm that backs founders across many industries, aiming to build long-term relationships and support companies across multiple stages and milestones.
Parkwalk Advisors is a UK-based investment manager focused on backing deeptech companies spun out of UK universities, bridging the gap between academic research and commercial success. It operates as part of IP Group plc and is a leading EIS fund manager.
Apollo Health Ventures is a biotech-focused investor that combines traditional funding with venture building to back transformative healthcare and longevity companies in Europe and the US.
Borealis Ventures is a venture capital firm focused on building and backing healthcare companies.
Firms observed investing alongside Oxford Science Enterprises, from public investor directories. Shared companies are the overlap with Oxford Science Enterprises's recorded portfolio.
Similar investors
DCVC (Data Collective) is a venture capital firm that backs founders building companies which apply technology to major challenges across areas such as energy, biotech, agriculture, and machine learning.
Amplitude Ventures is a Canadian healthcare venture capital firm focused on precision medicine, founded by former BDC partners Dion Madsen and Jean-François Pariseau. BDC Capital is an investor in its Fund I.
MaRS is a Toronto-based innovation hub and accelerator that supports Canadian startups from pre-seed funding through international expansion, offering workspace, mentorship, investor and customer connections, and sector-focused programming.
Innovation Industries is a deep tech investor backing companies with ground-breaking technologies aimed at addressing fundamental global challenges, providing support to help them scale and maximize environmental, social, and economic impact.
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests from seed to growth stages across artificial intelligence, health, and sustainability-focused technologies.